Tobramycin for the treatment of bacterial pneumonia in children

Recent advances in the treatment of Pseudomonas aeruginosainfections in cystic fibrosis

(2011) Niels Høiby   BMC Medicine

Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology

(2011) David E. Geller et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronicPseudomonas aeruginosainfection in cystic fibrosis

(2011) Michael D Parkins et al.   Expert Review of Respiratory Medicine

Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis

(2011) Roger Sorde et al.   Infection and Drug Resistance

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

(2010) Michael W. Konstan et al.   Journal of Cystic Fibrosis

Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa

(2010) R. Dhar et al.   THORAX

Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections

(2009) Ronald Gounden et al.   BMC INFECTIOUS DISEASES

Aerosol Antibiotics in Cystic Fibrosis

(2009) David E Geller   Respiratory Care

Aerosolized Antibiotics for Non-Cystic Fibrosis Bronchiectasis

(2008) Bruce K. Rubin   Journal of Aerosol Medicine and Pulmonary Drug Delivery